BlackRock Investment Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

BlackRock Investment Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.12M	Sell	11,302 -1,381	-11%	-$145K	﹤0.01%	2632
2016 Q3	$1.42M	Sell	12,683 -529	-4%	-$63.5K	﹤0.01%	2434
2016 Q2	$1.36M	Buy	13,212 +5,283	+67%	+$528K	﹤0.01%	2408
2016 Q1	$728K	Buy	7,929 +188	+2%	+$20.1K	﹤0.01%	2699
2015 Q4	$1.12M	Buy	7,741 +78	+1%	+$10.2K	﹤0.01%	2522
2015 Q3	$792K	Buy	7,663 +5,788	+309%	+$679K	﹤0.01%	2768
2015 Q2	$306K	Buy	+1,875	New	+$318K	﹤0.01%	3224

Other funds holding SIOX

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock Investment Management's SIOX Position: Q4 2016 in Review

BlackRock Investment Management reduced its Sio Gene Therapies Inc. Common Stock (SIOX) stake by 11% in Q4 2016, selling an estimated $145K and leaving 11,302 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2632.

BlackRock Investment Management first reported a position in SIOX in Q2 2015 and has held it in 7 quarters since. The position peaked at $1.42M in Q3 2016. 101 funds tracked by Wall St. Rank hold SIOX as of Q4 2016.

BlackRock Investment Management held 11,302 shares of Sio Gene Therapies Inc. Common Stock worth $1.12M as of Q4 2016.
BlackRock Investment Management sold 1,381 Sio Gene Therapies Inc. Common Stock shares in Q4 2016, an estimated $145K.
Sio Gene Therapies Inc. Common Stock made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2632 holding.
BlackRock Investment Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and has held it in 7 quarters since.
BlackRock Investment Management's Sio Gene Therapies Inc. Common Stock position peaked at $1.42M in Q3 2016.
101 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.